Home > Boards > US OTC > Biotechs > Sangamo Biosciences Inc. (SGMO)

RICHMOND, Calif., April 3, 2019 /PRNewswire/ -- Sangamo

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
ciciagt Member Profile
Member Level 
Followed By 20
Posts 2,213
Boards Moderated 0
Alias Born 01/02/03
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 6/14/2019 4:03:08 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:14:04 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:10:50 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:09:29 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:08:23 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:07:37 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/12/2019 5:05:40 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 5/17/2019 5:43:08 PM
Sangamo Therapeutics Announces Presentations At Upcoming Scientific, Medical And Investor Conferences PR Newswire (US) - 5/15/2019 4:30:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/14/2019 8:02:59 AM
Sangamo Therapeutics Announces Participation In The Bank Of America Merrill Lynch 2019 Health Care Conference PR Newswire (US) - 5/10/2019 8:30:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/8/2019 4:39:42 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/8/2019 4:19:31 PM
Sangamo Therapeutics Reports First Quarter 2019 Financial Results PR Newswire (US) - 5/8/2019 4:01:00 PM
Sangamo Therapeutics Announces First Quarter 2019 Conference Call And Webcast PR Newswire (US) - 5/1/2019 4:01:00 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 4/25/2019 4:36:32 PM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 4:34:05 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 4/18/2019 6:48:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/17/2019 4:46:57 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/16/2019 7:28:53 PM
Sangamo Therapeutics Announces Presentations At 2019 Annual Meeting Of The American Society Of Gene & Cell Therapy PR Newswire (US) - 4/15/2019 4:01:00 PM
Potential Blockbuster Gene Therapy Programs to Watch in 2019 NetworkNewsWire - 4/10/2019 8:45:00 AM
Sangamo Therapeutics Announces Completion of Public Offering of Common Stock and Exercise in Full of Underwriters' Option to ... PR Newswire (US) - 4/8/2019 4:01:00 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/4/2019 5:05:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 4/4/2019 5:03:51 PM
ciciagt Member Level  Wednesday, 04/03/19 11:17:14 PM
Re: None
Post # of 327 
RICHMOND, Calif., April 3, 2019 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced that it has commenced an underwritten public offering of shares of its common stock. All of the shares are being offered by Sangamo. In addition, Sangamo expects to grant the underwriters of the offering a 30-day option to purchase additional shares of its common stock at the public offering price, less the underwriting discounts and commissions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering will be completed, or as to the actual size or terms of the offering.

Sangamo anticipates using the net proceeds from the offering for working capital and other general corporate purposes, including support for its own and its partnered gene therapy, genome editing, cell therapy and gene regulation product candidates and research programs, its manufacturing facilities and other business development activities.
https://investor.sangamo.com/news-releases/news-release-details/sangamo-therapeutics-announces-proposed-public-offering-common-1

Public Reply | Private Reply | Keep | Last ReadPost New MsgPrevious | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist